Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study †

F. Van Gaal, Luc; Scheen, André; Rissanen, Aila; Rössner, Stephan; Hanotin, Corinne; Ziegler, Olivier

doi:10.1093/eurheartj/ehn076

Public

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study †

Published in European Heart Journal • Apr 15, 2008

Authors:

Luc F. Van Gaal

André Scheen

Aila Rissanen

Abstract

AIMS: Rimonabant, the first selective cannabinoid type 1 receptor blocker, has been shown to produce weight loss and improvements in several cardiometabolic risk factors over 1 year. We report the 2 year efficacy and tolerability data of rimonabant. METHODS AND RESULTS: Patients with a body mass ind...

Subject

Rimonabant

Medicine

Tolerability

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!